Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

Xiaozheng Dou; Dinesh Nath; Henry Shin; Elmar Nurmemmedov; Philip C. Bourne; Jian Xing Ma; Adam S. Duerfeldt

doi:10.1021/acs.jmedchem.9b01189

Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

Xiaozheng Dou, Dinesh Nath, Henry Shin, Elmar Nurmemmedov, Philip C. Bourne, Jian Xing Ma, Adam S. Duerfeldt

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Peroxisome proliferator-activated receptor alpha (PPARα) is expressed in retinal Müller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPARα with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPARα is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPARα over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

Original language	English (US)
Pages (from-to)	2854-2876
Number of pages	23
Journal	Journal of medicinal chemistry
Volume	63
Issue number	6
DOIs	https://doi.org/10.1021/acs.jmedchem.9b01189
State	Published - Mar 26 2020
Externally published	Yes

Bibliographical note

Funding Information:
Research reported in this publication was supported by the University of Oklahoma Growth Fund (A.S.D., H.S., J.-X.M.) and the National Eye Institute of the National Institutes of Health under award numbers R21EY028279 (A.S.D.), R01EY019309, R01EY018659, and R01EY012231 (J.-X.M.). We acknowledge the use of the Protein Production Core (PPC) at the University of Oklahoma, Norman. PPC is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103640. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors are grateful to Cameron D. Siler and Will Drover for enlightening discussions and Eurofins for conducting the PK studies.

Publisher Copyright:
Copyright © 2020 American Chemical Society.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1021/acs.jmedchem.9b01189

Find It

Find It at U of M Libraries

Cite this

@article{1d66eae9c6514cb28f56cfedf633af69,

title = "Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders",

abstract = "Peroxisome proliferator-activated receptor alpha (PPARα) is expressed in retinal M{\"u}ller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPARα with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPARα is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPARα over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.",

author = "Xiaozheng Dou and Dinesh Nath and Henry Shin and Elmar Nurmemmedov and Bourne, {Philip C.} and Ma, {Jian Xing} and Duerfeldt, {Adam S.}",

note = "Funding Information: Research reported in this publication was supported by the University of Oklahoma Growth Fund (A.S.D., H.S., J.-X.M.) and the National Eye Institute of the National Institutes of Health under award numbers R21EY028279 (A.S.D.), R01EY019309, R01EY018659, and R01EY012231 (J.-X.M.). We acknowledge the use of the Protein Production Core (PPC) at the University of Oklahoma, Norman. PPC is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103640. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors are grateful to Cameron D. Siler and Will Drover for enlightening discussions and Eurofins for conducting the PK studies. Publisher Copyright: Copyright {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = mar,

day = "26",

doi = "10.1021/acs.jmedchem.9b01189",

language = "English (US)",

volume = "63",

pages = "2854--2876",

journal = "Journal of medicinal chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "6",

}

TY - JOUR

T1 - Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

AU - Dou, Xiaozheng

AU - Nath, Dinesh

AU - Shin, Henry

AU - Nurmemmedov, Elmar

AU - Bourne, Philip C.

AU - Ma, Jian Xing

AU - Duerfeldt, Adam S.

N1 - Funding Information: Research reported in this publication was supported by the University of Oklahoma Growth Fund (A.S.D., H.S., J.-X.M.) and the National Eye Institute of the National Institutes of Health under award numbers R21EY028279 (A.S.D.), R01EY019309, R01EY018659, and R01EY012231 (J.-X.M.). We acknowledge the use of the Protein Production Core (PPC) at the University of Oklahoma, Norman. PPC is supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103640. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors are grateful to Cameron D. Siler and Will Drover for enlightening discussions and Eurofins for conducting the PK studies. Publisher Copyright: Copyright © 2020 American Chemical Society.

PY - 2020/3/26

Y1 - 2020/3/26

N2 - Peroxisome proliferator-activated receptor alpha (PPARα) is expressed in retinal Müller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPARα with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPARα is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPARα over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

AB - Peroxisome proliferator-activated receptor alpha (PPARα) is expressed in retinal Müller cells, endothelial cells, and in retinal pigment epithelium; agonism of PPARα with genetic or pharmacological tools ameliorates inflammation, vascular leakage, neurodegeneration, and neovascularization associated with retinal diseases in animal models. As such, PPARα is a promising drug target for diabetic retinopathy and age-related macular degeneration. Herein, we report proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and preliminary pharmacokinetic assessment of a first-generation lead 4a (A91). Additionally, we present the design, synthesis, and evaluation of second-generation analogues, which led to the discovery of 4u and related compounds that reach cellular potencies <50 nM and exhibit >2,700-fold selectivity for PPARα over other PPAR isoforms. These studies identify a pipeline of candidates positioned for detailed PK/PD and pre-clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=85082542684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082542684&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.9b01189

DO - 10.1021/acs.jmedchem.9b01189

M3 - Article

C2 - 32096640

AN - SCOPUS:85082542684

SN - 0022-2623

VL - 63

SP - 2854

EP - 2876

JO - Journal of medicinal chemistry

JF - Journal of medicinal chemistry

IS - 6

ER -

Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this